Ani S. Balmanoukian, MD
The landscape of genitourinary (GU) malignancies is rapidly evolving, with promising immunotherapy breakthroughs in renal cell carcinoma (RCC) and urothelial carcinoma.
State of the Science Summit™ on Genitourinary Cancers. In an interview during the meeting, she highlighted the focal points of her presentation.
OncLive: Please give an overview of your lecture on advances with immunotherapy in GU cancers.
: The field has come a long way since the initial introduction of checkpoint inhibitors a few years ago. There have been significant advancements in checkpoint inhibitors in the last 2 years in both RCC and urothelial carcinoma. At the 3-year mark, we are seeing significant differences and improvements in median OS with nivolumab versus everolimus in RCC.
... to read the full story